Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy.
Adult
Aged
Bronchoalveolar Lavage Fluid
/ cytology
COVID-19
/ epidemiology
Critical Illness
/ epidemiology
Female
Humans
Intensive Care Units
Italy
/ epidemiology
Leukocyte Count
Lymphocytes
/ cytology
Macrophages
/ cytology
Male
Middle Aged
Neutrophils
/ cytology
Pneumonia, Viral
/ epidemiology
Respiration, Artificial
SARS-CoV-2
/ immunology
Survivors
/ statistics & numerical data
Treatment Outcome
Bronchoalveolar lavage fluid
COVID-19
Lymphocytes
Macrophages
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Apr 2021
15 Apr 2021
Historique:
received:
29
11
2020
accepted:
10
03
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
21
4
2021
Statut:
epublish
Résumé
The primary objective of the study is to describe the cellular characteristics of bronchoalveolar lavage fluid (BALF) of COVID-19 patients requiring invasive mechanical ventilation; the secondary outcome is to describe BALF findings between survivors vs non-survivors. Patients positive for SARS-CoV-2 RT PCR, admitted to ICU between March and April 2020 were enrolled. At ICU admission, BALF were analyzed by flow cytometry. Univariate, multivariate and Spearman correlation analyses were performed. Sixty-four patients were enrolled, median age of 64 years (IQR 58-69). The majority cells in the BALF were neutrophils (70%, IQR 37.5-90.5) and macrophages (27%, IQR 7-49) while a minority were lymphocytes, 1%, TCD3+ 92% (IQR 82-95). The ICU mortality was 32.8%. Non-survivors had a significantly older age (p = 0.033) and peripheral lymphocytes (p = 0.012) were lower compared to the survivors. At multivariate analysis the percentage of macrophages in the BALF correlated with poor outcome (OR 1.336, CI95% 1.014-1.759, p = 0.039). In critically ill patients, BALF cellularity is mainly composed of neutrophils and macrophages. The macrophages percentage in the BALF at ICU admittance correlated with higher ICU mortality. The lack of lymphocytes in BALF could partly explain a reduced anti-viral response.
Sections du résumé
BACKGROUND
BACKGROUND
The primary objective of the study is to describe the cellular characteristics of bronchoalveolar lavage fluid (BALF) of COVID-19 patients requiring invasive mechanical ventilation; the secondary outcome is to describe BALF findings between survivors vs non-survivors.
MATERIALS AND METHODS
METHODS
Patients positive for SARS-CoV-2 RT PCR, admitted to ICU between March and April 2020 were enrolled. At ICU admission, BALF were analyzed by flow cytometry. Univariate, multivariate and Spearman correlation analyses were performed.
RESULTS
RESULTS
Sixty-four patients were enrolled, median age of 64 years (IQR 58-69). The majority cells in the BALF were neutrophils (70%, IQR 37.5-90.5) and macrophages (27%, IQR 7-49) while a minority were lymphocytes, 1%, TCD3+ 92% (IQR 82-95). The ICU mortality was 32.8%. Non-survivors had a significantly older age (p = 0.033) and peripheral lymphocytes (p = 0.012) were lower compared to the survivors. At multivariate analysis the percentage of macrophages in the BALF correlated with poor outcome (OR 1.336, CI95% 1.014-1.759, p = 0.039).
CONCLUSIONS
CONCLUSIONS
In critically ill patients, BALF cellularity is mainly composed of neutrophils and macrophages. The macrophages percentage in the BALF at ICU admittance correlated with higher ICU mortality. The lack of lymphocytes in BALF could partly explain a reduced anti-viral response.
Identifiants
pubmed: 33858331
doi: 10.1186/s12879-021-06015-9
pii: 10.1186/s12879-021-06015-9
pmc: PMC8049078
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
353Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Inform Health Soc Care. 2013 Dec;38(4):313-29
pubmed: 23957714
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Eur Respir J. 2020 May 21;55(5):
pubmed: 32341111
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Respir Care. 2016 May;61(5):658-67
pubmed: 26837732
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Lancet Infect Dis. 2020 May;20(5):515-516
pubmed: 32213336
Chest. 2020 Jul;158(1):195-205
pubmed: 32224074
Clin Infect Dis. 2021 Jan 23;72(1):182-183
pubmed: 32474605
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Eur Respir J. 2001 Apr;17(4):791-801
pubmed: 11401077
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Eur Respir J. 1989 Jun;2(6):561-85
pubmed: 2663535
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Semin Immunopathol. 2017 Jul;39(5):541-550
pubmed: 28555383
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
Clin Immunol. 2020 May;214:108393
pubmed: 32222466